Monte Rosa Therapeutics, Inc. GLUE Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s accounts payable?
- Monte Rosa Therapeutics, Inc. (GLUE) reported accounts payable of $7.9M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s accounts payable changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s accounts payable increased by 21.7% year-over-year, from $6.49M to $7.9M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s accounts payable has grown at a -12.9% compound annual growth rate (CAGR), from $7.07M to $3.55M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.